SCII.OB: Summary for STEM CELL THERAPY - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 2:52am EST - Canadian Markets open in 6 hours and 38 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Stem Cell Therapy International Corporation (SCII.OB)

On Feb 9: 0.111 USD

0.009 (7.50%)

MORE ON SCII.OB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

STEM CELL THERAPY (OTC BB:SCII.OB) Delayed quote data

Last Trade:	0.111 USD
Trade Time:	Feb 9
Change:	0.009 (7.50%)
Prev Close:	0.12
Open:	0.115
Bid:	0.105 x 5000
Ask:	0.111 x 5000
1y Target Est:	N/A

Day's Range:	0.105 - 0.115
52wk Range:	0.03 - 0.50
Volume:	118,600
Avg Vol (3m):	337,895
Market Cap:	N/A
P/E (ttm):	N/A
EPS (ttm):	-0.028
Div & Yield:	N/A (N/A%)

Stem Cell Therapy International Corporation (SCII.OB)

1d 5d 3m 6m 1y 2y 5y

Add SCII.OB to Portfolio

Download Data

HEADLINES

•	STEM CELL THERAPY INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statem
	EDGAR Online (Tue 2:29pm)

•	Stem Cell Therapy board elects HistoStem CEO Hoon Han chairman
	at bizjournals.com (Tue 2:05pm)

•	Dr. Hoon Han Elected Chairman of the Board of Stem Cell Therapy International
	Marketwire (Tue 11:30am)

•	Histostem Participates in Successful Stem Cell Treatment for Acute Spinal Cord Injury in Dogs
	Marketwire (Mon, Feb 8)

•	STEM CELL THERAPY INTERNATIONAL, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Changes
	EDGAR Online (Wed, Feb 3)

•	Stem Cell Therapy closes merger with Histostem
	at bizjournals.com (Mon, Feb 1)

•	Stem Cell Therapy International, Inc. Closes Merger With Histostem Ltd.
	Marketwire (Mon, Feb 1)

•	STEM CELL THERAPY INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statem
	EDGAR Online (Tue, Jan 12)

•	Stem Cell Therapy names Rick van den Toorn to board
	at bizjournals.com (Tue, Jan 12)

•	Stem Cell Therapy Appoints New Board Member
	Marketwire (Tue, Jan 12)

More Headlines for SCII.OB...

BUSINESS SUMMARY

Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education,...

Full Company Profile

Add to Portfolio

Email to a Friend

•